Global health inequity has many dimensions, and strategies are needed to address each of these. Some dimensions relate to the problem of access to quality and state-of-the-art care. In particular, access to medicines beyond the Essential Medicines to include the products of biopharma are beyond reach either due to care setting limitations, cost, or unawareness of availability. This inequity is MEDICINAL INEQUITY. Similarly, access to state-of-the-art medical technology has suffered for similar reasons but also because of the lack of support for physicians and hospitals by the producers of such technologies. This panel discussion will detail the practical and logistical challenges of migrating medicines and technologies to patients in the developing world. Most importantly, the panel will describe strategies for overcoming these limitations and challenge the audience with specific approaches and interventions that they and their companies can adopt to drive global health equity.